Show simple item record

"The challenge facing renal artery revascularization: what have we not proven and why we must"?

dc.contributor.authorHynes, B G
dc.contributor.authorMargey, R
dc.contributor.authorMoran, D
dc.contributor.authorRuggiero, N J
dc.contributor.authorKiernan, T J
dc.contributor.authorJaff, M R
dc.date.accessioned2012-01-04T16:30:02Z
dc.date.available2012-01-04T16:30:02Z
dc.date.issued2012-01-04T16:30:02Z
dc.identifier.citation"The challenge facing renal artery revascularization: what have we not proven and why we must"?, 110 (6):575-83 Acta Chir. Belg.en
dc.identifier.issn0001-5458
dc.identifier.pmid21337836
dc.identifier.urihttp://hdl.handle.net/10147/200077
dc.descriptionEndovascular renal artery stent therapy for atherosclerotic renal artery stenosis (RAS) is associated with excellent acute technical success, low complication rates and acceptable long-term patency. However, the clinical benefits to patients of renal artery stenting remain uncertain. To facilitate debate regarding the treatment of RAS, we need to understand the epidemiology, basic physiology and clinical consequences of renal artery stenosis. We must attempt to determine which patients are likely to benefit from renal artery stenting, assess the nuances of the percutaneous procedure and review the current literature pertaining to renal artery stenting.en
dc.description.abstractEndovascular renal artery stent therapy for atherosclerotic renal artery stenosis (RAS) is associated with excellent acute technical success, low complication rates and acceptable long-term patency. However, the clinical benefits to patients of renal artery stenting remain uncertain. To facilitate debate regarding the treatment of RAS, we need to understand the epidemiology, basic physiology and clinical consequences of renal artery stenosis. We must attempt to determine which patients are likely to benefit from renal artery stenting, assess the nuances of the percutaneous procedure and review the current literature pertaining to renal artery stenting.
dc.language.isoenen
dc.subject.meshAngioplasty, Balloon
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAtherosclerosis
dc.subject.meshClinical Trials as Topic
dc.subject.meshDisease Progression
dc.subject.meshHumans
dc.subject.meshHypertension
dc.subject.meshImmunoglobulin Fab Fragments
dc.subject.meshPatient Selection
dc.subject.meshPlatelet Glycoprotein GPIIb-IIIa Complex
dc.subject.meshPractice Guidelines as Topic
dc.subject.meshRecurrence
dc.subject.meshRenal Artery Obstruction
dc.subject.meshSeverity of Illness Index
dc.subject.meshStents
dc.subject.meshTreatment Outcome
dc.subject.meshVascular Patency
dc.title"The challenge facing renal artery revascularization: what have we not proven and why we must"?en
dc.typeArticleen
dc.contributor.departmentSection of Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston MA, USA.en
dc.identifier.journalActa chirurgica Belgicaen
dc.description.provinceMunster
html.description.abstractEndovascular renal artery stent therapy for atherosclerotic renal artery stenosis (RAS) is associated with excellent acute technical success, low complication rates and acceptable long-term patency. However, the clinical benefits to patients of renal artery stenting remain uncertain. To facilitate debate regarding the treatment of RAS, we need to understand the epidemiology, basic physiology and clinical consequences of renal artery stenosis. We must attempt to determine which patients are likely to benefit from renal artery stenting, assess the nuances of the percutaneous procedure and review the current literature pertaining to renal artery stenting.


This item appears in the following Collection(s)

Show simple item record